ArticleInfection & chemotherapy2025
Evaluation of Reactogenicity and Neutralizing Antibody Responses 6 Months Post-Vaccination with Monovalent COVID-19 Vaccine.
Article in Infection & chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The association between reactogenicity and long-term immunogenicity after coronavirus disease 2019 (COVID-19) vaccination remains unclear. This study investigated whether adverse reactions to ChAdOx1 nCoV-19 or BNT162b2 vaccines correlate with neutralizing antibody responses in severe acute respiratory syndrome coronavirus 2 infection-naïve healthcare workers. Blood samples were collected at three time points to measure neutralizing antibodies. Among 123 participants (ChAdOx1 nCoV-19, n=88; BNT162b2, n=35), local and systemic reactions were not significantly associated with antibody responses at six months post-vaccination for either vaccine type. No significant interactions between symptoms, time points, or age were observed. These findings suggest that adverse reactions might not predict long-term neutralizing antibody levels following COVID-19 vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.